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Insights into the Pathogenesis and Treatment
of Cancer from Inborn Errors of Metabolism
Ayelet Erez,1,3,5 Oleg A. Shchelochkov,1,5,6 Sharon E. Plon,1,2,3 Fernando Scaglia,1,3,*
and Brendan Lee1,2,3,4,*Mutations in genes that play fundamental roles inmetabolic path-
ways have been found to also play a role in tumor development
and susceptibility to cancer. At the same time, significant progress
has been made in the treatment of patients with inborn errors of
metabolism (IEM),1 resulting in increased longevity and the un-
masking of cancer predisposition, frequently hepatocellular carci-
noma, in these conditions. These patients offer a potential oppor-
tunity to deepen our understanding of how intermediary
metabolism impacts tumorigenesis. We provide an overview
from the perspective of cancers in patients affected with IEM
and discuss how dysregulation of these specific metabolic path-
ways might contribute to the mechanisms of cancer development
and treatment.
Introduction
More than 50 years ago, Warburg initiated research on
mitochondrial alterations in cancer and proposed amecha-
nism to explain the differences in energy metabolism
between normal and cancer cells, suggesting that mito-
chondrial alterations could provide unique therapeutic
targets in various cancer types.2 Warburg’s major insight
was the proposition that metabolic changes observed in
cancer are the primary changes that lead to its develop-
ment rather than a secondary result of the malignant
transformation.2 Since then, several metabolic pathways
have been found to be dysregulated in cancer, enabling
cancer cells to acquire and metabolize nutrients necessary
to meet the requirements of heightened proliferation.
Understanding the existing cross-talk between cellular
metabolism and growth control has resulted in a better
understanding of normal and disease processes and facili-
tated the discovery of new treatment modalities in
oncology, for example, trastuzumab and imatinib.3,4
Inborn errors of metabolism (IEM)1 result in the disrup-
tion of a wide range of metabolic pathways including but
not limited to the metabolism of proteins, carbohydrates,
lipids, nucleic acids, steroids, and metals. IEM can result
from a deficiency or overactivity of an enzyme, a deficiency
of a cofactor required for enzymatic activity, an abnor-
mality in degradation or in the transport processes that
leads to the accumulation of upstream metabolites, a defi-
ciency of a downstream metabolite, or a diversion of the1Department of Molecular and Human Genetics, Baylor College of Medicine, H
cine, Houston, TX 77030, USA; 3Texas Children’s Hospital, Houston, TX 7703
5These authors contributed equally to this work
6Present address: Department of Pediatrics, University of Iowa Hospitals and C
*Correspondence: fscaglia@bcm.edu (F.S.), blee@bcm.edu (B.L.)
DOI 10.1016/j.ajhg.2011.03.005. 2011 by The American Society of Human
402 The American Journal of Human Genetics 88, 402–421, April 8, 2affected metabolic flux to secondary pathways.5 The avail-
ability of lifesaving treatments for patients with IEM has
made early diagnosis of metabolic disorders crucial, thus
stimulating the adoption of mandatory neonatal screening
programs resulting in at least a 5-fold increase in the
annual detection rate as compared to the previous
20 years.6 This increase is at least partially explained by
the diagnosis of infants with milder forms of IEM who
would not have come to medical attention without the
introduction of expanded newborn screening. Several
large screening programs, such as the New England
Newborn Screening Program and Pediatrix Analytical,
have estimated that 1 in 4000 newborns might have
a confirmedmetabolic disorder.7,8 As a result, prompt diag-
nosis with early implementation of tailored therapy has
resulted inmore successful interventions and, most impor-
tantly, improved survival.6,9,10 In several IEM, longer
survival rates have unmasked a susceptibility to cancer,
as seen in glycogen storage disease IV11,12 (GSD IV [MIM
232500]). Hence, with accumulating experience, improved
detection of IEMwill allow surveillance and early interven-
tion that could result in preferred outcomes of the IEM but
could also lead to earlier detection of complications such as
hepatocellular carcinoma (HCC) in tyrosinemia type 1
(caused by mutations in FAH [MIM 276700]) and citrin
deficiency (MIM 603859).
Most metabolic disorders are inherited as autosomal-
recessive conditions, and clinical problems are evident
when the child inherits mutations in both alleles of the
implicated gene. Typically, the heterozygous individual is
healthy without evidence of disease because one normal
allele is usually sufficient to maintain the rate of a reaction
catalyzed by the encoded enzyme. However, having one
mutant germline allele in every cell in the body as well
as additional somatic events or second hits results in bial-
lelic inactivation and somatic deficiency that can lead to
carcinogenesis. Hence, individuals without a clinically
evident metabolic disorder might demonstrate suscepti-
bility to cancer as a result of inheriting single inactivating
mutations in metabolic genes, for example, those encod-
ing fumarate hydratase (FH [MIM 136850]) or subunits ofouston, TX 77030, USA; 2Department of Pediatrics, Baylor College of Medi-
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succinate dehydrogenase13 (SDHA [MIM 600857]). On the
other hand, patients with IEM generally have near
complete loss of enzyme function in every cell in the
body because of two germline genomic changes, thus
recurring patterns of cancers associated with specific IEM
suggest a common genetic etiology and underscore the
importance of specific metabolic dysregulation in the
pathogenesis of cancer.
There are multiple ways by which IEM can predispose to
cancers: accumulation of toxic metabolites, as seen with
hereditary hemochromatosis (HFE-related HHC [MIM
235200] causing liver cirrhosis) and HCC; increased rate
of mutations as seen in mitochondrial disorders; or by
channeling metabolites to pathways preferentially used
by cancer cells as aerobic glycolysis.3 Hence, the dissection
of a unique genetic and biochemical profile in a given IEM
with a predisposition to a specific cancer offers an opportu-
nity to understand the mechanisms of tumorigenesis of
common cancers (Table 1).
Here, we review the prototypical biochemical features of
IEM and their specific associated cancer predispositions.
We discuss possible mechanisms leading to the specific
cancer with an emphasis on the description of the dysregu-
lated pathway. In addition, we give examples as to how the
knowledge gained from specific metabolic changes led to
the development of new therapeutic approaches to cancer.IEM Pathogenesis and Cancer Mechanism
This section describes potential mechanisms involved in
cancer development as related to specific IEM, which result
in three different types of insults: (1) toxic accumulation of
metabolites, (2) metabolite channeling, and (3) mitochon-
drial dysfunction. We hypothesize that the underlying
metabolic disorder impacts the early stages of tumorigen-
esis/carcinogenesis as opposed to cancer progression.
Hence we focus on the primarymetabolic event that might
lead to cancer initiation.
Accumulation of Toxic Metabolites
Enzyme deficiencies resulting in IEM generally cause accu-
mulation of the enzyme’s substrate and a deficiency of its
downstream product (Figure 1).14 In some cases, the accu-
mulation of substrate is toxic, as seen in GSD, whereas in
others the accumulation of toxic metabolite leads to an
increase in oxidative stress and reactive oxygen species
(ROS), as seen with iron accumulation in hemochroma-
tosis.15 In addition, accumulation of toxic metabolite
could affect gene expression or cause a shift to alternative
metabolic pathways, which could lead to tumorigenesis.16
Because the liver is the organ in the bodywheremostmeta-
bolic pathways are active, the toxic accumulation often
results in cirrhosis-promoting HCC. Hence, although
malignant liver tumors are an unusual cancer in children,
accounting for approximately 1% of childhood malignan-
cies,17 HCC is one of the most common cancers observed
with IEM.The AmHCC is seen in citrin deficiency;18 tyrosinemia type I;19
hemochromatosis;20 porphyrias21 (AIP [MIM 176000]);
Wilson disease22 (MIM 277900); Gaucher disease23 (GD
[MIM 230800]); GSD I24 (MIM 232200), GSD III25 (GSD
III [MIM 232400]), and IV;11 alpha 1-antitrypsin defi-
ciency26 (AATD [MIM 613490]); and MDDS.27 The variety
of different IEM predisposing to HCC suggests that it
might not be directly linked to the genetic disorder per se
but rather to the chronic and cumulative toxic damage
causing liver fibrosis and cirrhosis eventually leading to
HCC. Hence, cirrhosis could be one of the common mech-
anisms by which multiple IEM result in HCC.28 In spite of
this potential common pathway, it should be noted that
each of the IEM described here has its own specific toxin
accumulation that, in addition to cirrhosis and HCC, could
promote other malignancies through different mecha-
nisms. Of note, in a few IEM, for example in GSD I29 and
hereditary hemochromatosis, HCC has been described in
the absence of cirrhosis, supporting the involvement of
other mechanisms.20
Tyrosinemia type 1 results from the deficiency of fumar-
ylacetoacetate hydrolase, which catalyzes the last step in
the tyrosine degradation pathway.30,31 Biochemically,
FAH deficiency is characterized by accumulation of fumar-
ylacetoacetate, maleylacetoacetate, succinylacetoacetate,
and succinylacetone. The last compound is excreted in
large quantities in the urine and is widely used as
a screening and confirmatory test for FAH deficiency.31
The disease is seen in high frequency in Saguenay-Lac St.
Jean region of the province of Quebec, Canada and in
Northern Europe. Clinically, tyrosinemia type 1 is charac-
terized by acute and chronic liver failure with varying
age of onset.32 The risk of HCC is high, and about 40%
of patients who survive beyond 2 years of age develop
HCC.28 It has been suggested that tumorigenic effects are
linked to the ability of accumulated fumarylacetoacetate,
maleylacetoacetate, and succinylacetone to disrupt thiol
groups of proteins.33 In addition, fumarylacetoacetate
was reported to be a direct mutagen,34 probably because
of its alkylating properties. It has been demonstrated
that nuclear factor erythroid-2-related factor 2 (Nrf2),
a transcription factor participating in protection against
oxidative stress, plays a central role in fumarylacetoace-
tate-induced liver damage.19 A combination of ROS and
the mutagenic properties of accumulated compounds in
FAH deficiency results in primary liver cancer manifesting
as HCC in 17%–37% of untreated patients.35,36 Treatment
with 2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexane-
dione (NTBC) prevents the accumulation of toxic metabo-
lites and significantly decreases the incidence of HCC
to <2% in these patients if administered in their first
year of life.37
HFE-related hereditary hemochromatosis is an inborn
error of iron metabolism caused by mutations in HFE-en-
coding (MIM 613609) hereditary hemochromatosis
protein.38,39 The gene product binds to the transferrin
receptor and reduces its affinity for iron-loaded transferrin.erican Journal of Human Genetics 88, 402–421, April 8, 2011 403
Table 1. IEM and Associated Tumors
IEM Gene
Associated Tumors,
Cancers and Syndromes
Proposed Mechanisms
of Tumorigenesis References
Tyrosinemia type 1 FAH HCC Fumarylacetoacetate, maleylacetoacetate,
and succinylacetone can disrupt
SH-groups of proteins and increase
the damaging effects of ROS;
fumarylacetoacetate can also
be a direct mutagen
18, 26,
28-34
HFE-related hereditary
hemochromatosis
HFE HCC Iron itself is carcinogenic and its
accumulation increases oxidative tissue
damage leading to carcinogenesis.
19, 35–42
Acute intermittent
porphyria
HMBS HCC The final oxidation product
of 5-aminolevulinate,
4,5-dioxovalerate might result
in DNA alkylation and mutagenesis
20, 44–46,
49–50
PCT UROD HCC Associated iron overload
might result in carcinogenesis.
47–48
Wilson disease ATP7B HCC, cholangiocarcinoma,
and abdominal
adenocarcinoma
Dysregulation of the copper metabolism
might result in the abnormal cytochrome c
oxidase and mitochondria superoxide
dismutase, thus altering ROS
51–56
GD GBA Hematologic malignancies,
bone cancer
Abnormal stimulation of
cells responsible for adaptive
immunity by glucocerebroside-laden
macrophages; increased stress of
endoplasmic reticulum
57–61
AAT SERPINA1 HCC Accumulation of aggregated AAT
with additional mitochondrial damage
64–71
Fabry disease GLA RCC Chronic accumulative renal injury 72–76
GSD I, III, and IV G6PC
SLC37A4
AGL
GBE1
HCC Increased flux through the P5P pathway
with altered DNA and RNA synthesis;
diversion of fatty acid flux from
beta-oxidation in the mitochondria
into peroxisomes favoring production
of H2O2; activation of proto-oncogenes
through dysregulation of the
insulin-glucagon-growth hormone trio
23–24,
26–27,
79–88
SDH deficiency SDHA
SDHB
SDHC
SHDD
Carney triad (paraganglioma,
gastric stromal tumors
and pulmonary chondromas),
Carney-Stratakis syndrome;
renal tumors and
pheochromocytomas
Accumulation of succinate and
fumarate cause a pseudohypoxia
state resulting in an inhibition of HIF
hydroxylases, leading to stabilization
of activated HIF-1a and expression
of HIF target proteins such as VEGF.
Severe disturbance in the electron
transport chain can lead to
dysregulated ROS production
12, 15,
89–92,
96–106
FH deficiency FH Cutaneous leiomyomas, uterine
leiomyomas, adrenocortical tumors,
early-onset renal cell cancer, ovarian
mucinous cystadenomas, Leydig
cell tumors, leiomyosarcomas,
and cerebral cavernomas
93–95
L-2-hydroxyglutaric
aciduria
L2HGDH Brain gliomas and glioblastomas,
Wilms tumor, acute
myeloblastic leukemia
L-2-hydroxyglutarate can promote
Warburg effect and inhibition
of HIF prolyl hydroxylase
107–110
Isocitrate dehydrogenase
deficiency
IDH1
IDH2
Brain gliomas and glioblastomas Specific mutations in IDH1 and IDH2
might deplete a-KG by converting it into
D-2-hydroxyglutarate, thus interfering
with prolyl hydroxylases and
inhibiting oxidative phosphorylation.
111–120
Citrin deficiency
(AGC2)
SLC25A13 HCC Increased uptake of thymidine
promoting growth and inhibiting
apoptosis secondary to unbalanced
dNTP pools. Increased NADH/NADþ
ratio stimulating fatty acid synthesis,
steatosis and liver damage.
Dysregulation of ROS.
121–126
(Continued on next page)
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Table 1. Continued
IEM Gene
Associated Tumors,
Cancers and Syndromes
Proposed Mechanisms
of Tumorigenesis References
Deoxyguanosine
kinase deficiency
DGUOK HCC Unbalanced dNTP pools
resulting in DNA mutations;
increased generation of ROS;
131–140
MPV17 deficiency MPV17 HCC Mitochondrial DNA depletion
resulting in the reduction
of oxidative phosphorylation
and dysregulation of the
ROS biology
141
MERRF tRNA-Lys
(m.8344A > G)
Lipomas Decrease in oxidative
phosphorylation
142–145
The table summarizes the IEM described in this review with the unique tumors that were found to be associated with each specific IEM. In addition, a proposed
mechanism of tumorgenesis is suggested. Roman typeface indicates IEM related to accumulation of toxic metabolites; Italics indicate IEM related to metabolite
channeling; Bold indicates IEM-related aberrant mitochondrial function.Thus, loss of HFE function results in deposition of iron in
most peripheral organs, including the liver. Hereditary
hemochromatosis is the most common autosomal-reces-
sive disorder in those of Northern European descent,
affecting 1 in every 200–400 individuals.39Many individ-
uals who carry two HFE mutations are healthy and show
no iron overload. Affected individuals typically present
between 40 and 60 years of age. In patients with clinically
diagnosedHFE-related hemochromatosis, HCC is common
and is responsible for 25%–45% of deaths.20,40 Risk factors
associated with HCC in HFE-related HHC include livertoacetate; FAH, fumarylacetoacetate hydrolase; G6PC, glucose-6-p
protein (HFE-related hereditary hemochromatosis); HMBS, hydro
porphyria); MAA, maleylacetoacetate; MPV17, MPV17 mitochondria
DNA depletion syndrome); ROS, reactive oxygen species; SA, succin
chondrial aspartate-glutamate carrier protein, citrin deficiency); SLC
uroporphyrinogen decarboxylase (familial PCT and hepatoerythropo
The Amcirrhosis, infections with hepatitis B or C, alcoholism,
and use of tobacco.20 Consistent with the deposition of
iron in all tissues, there might be increased risk of cancers
in other tissues including melanoma, esophageal, ovarian,
breast, hematologic, colorectal, and gastric malignan-
cies.41–43 In addition, HCC was described in HHC in the
absence of cirrhosis and even after reversal of cirrhosis
with therapy.44 These reports suggest that iron accumula-
tion could be involved in oxidative tissue damage directly
leading to carcinogenesis.45 Indeed, iron was shown to be
carcinogenic in animal models, and moreover, the use ofFigure 1. DiverseMechanisms of Tumor-
igenesis in Primary Liver Cancer
Biochemically diverse metabolic disorders
have primary liver cancer (HCC), which
can occur even in the absence of discern-
ible liver fibrosis or cirrhosis, as one of
their later complications. Unique bio-
chemical signatures in each metabolic
disorder provide us with important clues
regarding the dysregulation of major path-
ways instigating the transformation of
healthy tissue into a tumor. Several
common mechanisms emerge including
(1) direct mutagenesis via interaction of
intermediate metabolites with DNA, (2)
imbalances in the nucleotide pool result-
ing in mitochondrial DNA damage, (3)
dysregulation of ROS biology, and (4)
diversion of the metabolic flux imitating
Warburg effect. Although each mecha-
nism alone is unlikely to be directly
responsible for primary liver cancer, collec-
tively they lower the threshold required
for tissue transformation. The following
abbreviations are used: 4,5-DOV, 4,5-diox-
ovalerate; 5-ALA, 5-aminolevulinate;
ATP7B, ATPase Cuþþ transporting beta
polypeptide (Wilson disease); DGUOK,
deoxyguanosine kinase; FAA, fumarylace-
hosphatase, catalytic subunit (GSD Ia); HFE, hemochromatosis
xymethylbilane synthase (dominant disease acute intermittent
l inner membrane protein (hepatocerebral form of mitochondrial
ylacetone; SLC25A13, solute carrier family 25, member 13 (mito-
37A4, solute carrier family 37, member 4 (G6PT, GSD Ib); UROD,
etic porphyria).
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phlebotomy in people without IEM reduced cancer
risk.45,46
Disorders of heme metabolism encompass a large group
of heritable conditions disrupting synthesis of heme from
glycine and succinyl-CoA. Two hepatic forms of porphyria
have been shown to be linked to increased risk of devel-
oping HCC, including acute intermittent porphyria and
porphyria cutanea tarda (PCT).47,48
Acute intermittent porphyria is an autosomal-dominant
hepatic porphyria due to deleterious mutations in HMBS
(MIM 609806), encoding porphobilinogen deaminase.49,50
There is incomplete penetrance, and the majority of HMBS
mutation carriers are asymptomatic.50 The deficiency of
porphobilinogen deaminase in AIP is usually partial,
resulting in clinically latent disease in the absence of aggra-
vating factors. Clinical manifestations are seen when the
heme-mediated repression of the upstream 5-aminolevu-
linic acid synthetase I (ALAS1) is relieved in the liver.
This loss of feedback repression of ALAS1 usually occurs
when there is an increased requirement for heme that is
triggered by drugs inducing cytochrome P450 or
ALAS1.50 The restoration of this feedback loop by intrave-
nous administration of heme results in the repression of
ALAS1 and decrease in the synthesis of heme precursors
thought to be responsible for clinical manifestations of
this disease. Patients with AIP excrete significant amounts
of 5-aminolevulinate and porphobilinogen in the urine,
which can be used as a laboratory test for AIP diagnosis.
HCC is the only cancer known to be associated with
AIP.21 A retrospective population-based study involving
data on the population from northern Sweden determined
that 27% of deceased AIP patients had evidence of HCC.51
PCT (MIM 176100) is the most common form of
porphyria and is caused by a decrease in the activity of uro-
porphyrinogen decarboxylase, encoded by UROD52,53
(MIM 613521). Affected individuals develop adult-onset
light-sensitive dermatitis, often presenting with blisters in
the sun-exposed areas of skin. Biochemically, PCT patients
show increased uroporphyrin and heptacarboxyl
porphyrin in liver tissues, plasma, and urine.53 One
sporadic (type I) and two familial (types II and III) forms
have been described. Patients with PCT type I (sporadic)
demonstrate profoundly decreased activity of uroporphyri-
nogen decarboxylase but show no deleteriousmutations in
UROD. Factors that can affect the enzyme activity include
chronic infection with hepatitis C and HIV, alcohol and
tobacco use, estrogens, toxins (such as hexachlorobenzene
and halogenated polycyclic aromatic hydrocarbons), and
the accumulation of iron. The relevance of this last factor
can be observed in individuals with HHC, for whom the
associationbetweenPCT, ironoverload, andHFEmutations
has been described.54 PCT type II, an autosomal-dominant
trait, is caused by deleterious mutations in UROD.
The initial insult leading to cirrhosis and HCC or to
primary HCC in porphyria is thought to be alkylation of
DNA by 4,5-dioxovalerate, which the final oxidation
product of 5-aminolevulinate55 and increases mutation406 The American Journal of Human Genetics 88, 402–421, April 8, 2rates. In addition to HCC, oral, stomach, lung, prostate,
kidney, and bladder cancer have been shown to be signifi-
cantly increased in porphyria patients,48 as well as malig-
nancy of the breast, pancreas, or colon and hence should
be considered in patients presenting with an acute porphy-
ric attack in their late 30s–40s.56
Wilson disease is an autosomal-recessive hereditary
disorder of copper metabolism due to mutations in
ATP7B57,58 (MIM 606882). The gene encodes a copper-
transporting ATPase involved in the outward cellular efflux
of copper. It is most abundant in organs such as liver,
kidney, and brain. In the liver, the protein is responsible
for the efflux of copper into the bile; hence, the dysfunc-
tion of this transporter results in accumulation of copper
in hepatocytes. Clinical manifestations of the disease
include liver dysfunction and neurological and psychiatric
symptoms.58 HCC has been reported in approximately 6%
of affected individuals.59 Other malignancies include
cholangiocarcinoma and abdominal adenocarcinoma
without a known primary site. HCC in Wilson disease
has been primarily found in patients treated with D-peni-
cillamine with lower liver copper levels leading to the
hypothesis that copper accumulation might be protective
against hepatic carcinogenesis.60 However, HCC has been
described in an untreated Wilson patient as well as in rat
models of Wilson disease (Long-Evans Cinnamon rats),61
suggesting that copper’s carcinogenic effect might be
dosage dependent as well as influenced by other factors
such as D-penicillamine dosage and age at diagnosis.22,62
In addition, it has been suggested that copper’s role in
carcinogenesis could be related to its requirement for the
proper functioning of cytochrome c oxidase and mito-
chondrial superoxide dismutase; thus, imbalance in
copper pools could alter oxidative phosphorylation.63
GD is the most common lysosomal storage disease and
results from the deficiency of b-glucocerebrosidase (GBA
[MIM 606463]).64 Patients with GD accumulate glucocere-
broside in reticuloendothelial cells. Because of excessive
accumulation of glucocerebroside in bone marrow, both
cytopenia and bone lesions can occur. Hence, most
common malignancies observed in GD are hematologic
(lymphomas and multiple myeloma), together with
bone-related cancers.65,66 Chronic stimulation of the
immune response by glucocerebroside-laden macrophages
is one potential toxic mechanism.67,68 Indeed, in GD there
is an increased amount of circulating IgG and IgM anti-
bodies, suggesting underlying lymphoproliferation.
Others have proposed that leukocyte cellular function is
directly impacted by the underlying enzyme deficiency
rather than by chronic immune stimulation alone, which
would also contribute to the increased risk of hematologic
malignancy.65 As for the bone-related tumors, it is thought
that in GD, the occupancy of the bone marrow by
abnormal cells disturbs the interaction between bone and
bone marrow cells resulting in aberrant development and
activity of the bone cells and causing anomalous bone
remodeling predisposing to cancer.69 Although rarely,011
HCC has also been described in GD,23,70 as well as breast
cancer and melanoma, which were found to have a signifi-
cant association with this lysosomal storage disease.71
AATD is an autosomal-recessive disorder caused by
mutation in SERPINA172,73 (MIM 107400). The most
common manifestation is emphysema, which becomes
evident by the 30s to 40s, whereas a less commonmanifes-
tation is liver disease, which occurs in children and adults
and can result in cirrhosis, liver failure, and an increased
risk of developing HCC.26 Environmental factors, particu-
larly cigarette smoking, greatly increase the risk of emphy-
sema at an earlier age.73 The diagnosis of AATD relies on
the demonstration of a low plasma concentration of alpha
1-antitrypsin (AAT) and either observation of a deficient
variant of the protein AAT by protease inhibitor (PI) typing
or detection of mutations in both copies of SERPINA1.
PI*Z, resulting from p.Glu342Lys; c.1024G>A
[NM_000295.3 (we have numbered the mutation starting
from the second ATG), is the most common deficiency
allele and 95% of AATD are homozygous for it.74 The
AATmolecule is a serine PI that is predominantly produced
in the liver. Its most important physiologic functions are
the protection of pulmonary tissue from aggressive proteo-
lytic enzymes and regulation of pulmonary immune
processes. Hence, the basis for pulmonary disease in
AATD is a reduced inhibition of leukocyte elastase in the
lung, resulting in excessive destruction of the elastin in
the alveolae.75
Homozygosity as well as heterozygosity for AATD has
been shown to be related to the development of HCC.26
In the heterozygous state, HCCs frequently develop in
a noncirrhotic liver76 and are often characterized by chol-
angiocellular differentiation. The chronic liver injury in
AATD most probably results from accumulation of aggre-
gated AAT in hepatocytes and bile ducts.77 AAT aggregates
induce proinflammatory pathways and can be a stimulus
for hepatocarcinogenesis.78 In addition, there is evidence
for specific mitochondrial damage unique to AATD that
causes mitochondria autophagy, increasing the liver
damage, cirrhosis, and the predisposition to HCC.79
Similar to the finding that chronic toxic metabolite
exposure in the liver leads to HCC, bilateral renal cell carci-
noma (RCC) has been described in long-term Fabry disease
(MIM 301500).80,81 Fabry disease is an X-linked inborn
error of glycosphingolipid catabolism and results from
deficient or absent activity of the lysosomal enzyme
alpha-galactosidase A82 (GLA [MIM 300644]). This enzy-
matic defect leads to the systemic accumulation of globo-
triosylceramide (Gb3) and related glycosphingolipids in
the plasma and cellular lysosomes of vessels, nerves,
tissues, and organs throughout the body.82 Manifestations
of Fabry disease include serious and progressive impair-
ment of renal and cardiac function. In addition, patients
experience pain, gastrointestinal disturbance, transient
ischemic attacks, and strokes. Additional effects on the
skin, eyes, ears, lungs, and bones are often seen.83 Despite
the fact that the disease is X linked, heterozygous femalesThe Amcan present with clinical complications requiring medical
interventions and hence should not be considered
carriers.84
Two independent groups describe RCC in Fabry
patients.80,81 Although no clear etiologic relationship
between the metabolic and neoplastic phenotype has
been found yet, the common observation of RCC in Fabry
patients suggests this association to be more than coinci-
dental.80 Importantly, the likelihood of bilateral multifocal
RCC being an isolated finding is low and is typically asso-
ciated with known cancer susceptibility syndromes such as
familial RCC, Von Hippel-Lindau disease, polycystic
kidney disease, and tuberous sclerosis.80,81
Alteration of Metabolite Channeling
Cancer-associated metabolic programs include increased
rates of oxygen independent glycolysis, glutaminolysis,
and fatty acid synthesis (Figure 2A).85,86 These functional
changes in cell metabolism give transformed cells compet-
itive advantages for rapid proliferation. Glycolysis and
glutamine oxidation provide glucose and glutamine as
carbon sources for energy production and anabolism,
whereas the fatty acid synthesis provides lipids necessary
for membrane production and post translational modifica-
tions of proteins. For support fatty acid biosynthesis to
occur, there is an additional requirement for NADPH
generated by the pentose phosphate (P5P) pathway.
Hence, there is a shift in the glycolytic intermediate prod-
ucts intended to increase production of NADPH, lipid
synthesis, and nucleic and amino acids, all of which would
serve as building blocks to support rapid proliferation.85,86
Some overlapping metabolic features can be seen in
patients with GSDs and disorders of the tricarboxylic acid
cycle:87 increased anaerobic glycolysis, increased flux
through the P5P pathway, and alteration in the fatty acid
metabolism.
GSD I is an inborn error of metabolism characterized by
abnormal glycogen metabolism due to deficiency of
glucose-6-phosphatase complex88 (G6PC [MIM 613742]).
GSD I patients are unable to mobilize the glycogen stores
to offset fasting. They present with hepatomegaly, fasting
hypoglycemia, accumulation of glycogen, lactic acidosis,
hyperuricemia, and disturbance of the lipid metabolism.
Approximately 80% of cases (GSD Ia) result from muta-
tions in G6PC encoding glucose-6-phosphatase-a catalytic
unit. The remaining cases (GSD Ib) are due to mutations in
SLC37A4 encoding glucose-6-phosphate transporter
(G6PT [MIM 602671]). Sixteen percent of GSD Ia or GSD
Ib patients between ages 2 and 30 years develop hepatic
adenomas.89 These adenomas are frequently precancerous
and can carry up to a 10% risk of malignant transforma-
tion.90 The time between the diagnosis of liver adenomas
and HCC ranges from 0 to 28 years, and the age of HCC
diagnosis ranges between 19 and 49 years.24
GSD III is an autosomal-recessive disorder due to the
deficiency of glycogen debranching enzyme encoded by
AGL91 (MIM 610860). The enzyme possesses two catalyticerican Journal of Human Genetics 88, 402–421, April 8, 2011 407
Figure 2. Warburg Effect and Metabolic Disorders with Features of Metabolite Shunting
(A) The observedWarburg effect in cancerous cells is ametabolic phenomenon of aerobic glycolysis, that is, diversion of glucose via pyru-
vate to lactate even in the presence of abundant oxygen. In addition to the Warburg effect, other important features of metabolism in
cancerous cells include increased synthesis of nucleotides to synthesize DNA, diversion of citrate to cytosolic acetyl-CoA for fatty acid
synthesis, and increased need for glutamine, a precursor for alpha-ketoglutarate (a-KG), intrinsically linked to the HIF-pathway.
(B) The sumofmetabolic derangements observed inGSD Ia, where the inability to convert G6P to glucose results in increased shunting of
G6P to P5P pathway. G6P is also used as a substrate for fatty acid and triglyceride synthesis. Oversupply of lactate and pyruvate through
Cori cycle and hepatic gluconeogenesis could result in alteration of the ATP/ADP and NADH/NADþ ratios in favor of tumorigenesis.
(C) Metabolic abnormalities highlighting the role of Krebs cycle intermediates—succinate, fumarate, and a-KG—in the regulation of the
HIF-dependent pathway. Impaired function of Krebs cycle might adversely affect oxidative phosphorylation and thus lead to cell-auton-
omous shunting of glucose to pyruvate and lactate.
(D) Citrin deficiency is characterized by increased metabolism of simple carbohydrates resulting in high NADH/NADþ and lactate/pyru-
vate ratios, which can also be observed under theWarburg effect. Fatty liver in citrin deficiency implies increased flux of citrin via acetyl-
CoA for fatty acid synthesis.properties: amylo-1,6-glucosidase (EC 3.2.1.33) and
4-alpha-glucanotransferase (EC 2.4.1.25). The glucosidase
and transferase activities are mediated by two structurally
separate catalytic centers, but both are required for normal
functioning of the enzyme.92 In contrast to GSD I, patients
affected by GSD III can present with liver and muscle
phenotype and appear to be at increased risk for liver
fibrosis, often progressing to cirrhosis. Multiple reports
demonstrate the association between GSD III and HCC is
usually preceded by liver cirrhosis but not always by
hepatic adenomas, suggesting that both adenomas and
cirrhosis can contribute independently toward malignant
transformation.25,93 Although most GSD III patients have
both liver and muscle involvement, for reasons yet to be
elucidated, tumors do not appear to arise from the muscle
tissue.
Yet another form of glycogen storage disorder that has
been linked to primary liver cancer is GSD IV. The disease408 The American Journal of Human Genetics 88, 402–421, April 8, 2results from a deficiency of glycogen branching enzyme
because of mutations in GBE194 (MIM 607839). GSD IV
is a clinically heterogeneous condition and can affect liver,
muscle, and the central nervous system. Branching
enzyme deficiency leads to accumulation of abnormally
structured glycogen with longer branches and fewer
branching points, thus showing similarity to amylopectin,
found in plant starch.
HCChas been reported in GSD I,95 III,25 and IV.11,12,96 In
GSDs, the mechanism related to the development of HCC
has been frequently linked to liver cirrhosis. Cirrhosis from
any cause appears to be the common pathway by which
several risk factors exert their hepatocarcinogenic effect.28
However, GSD I is not associated with cirrhosis. Approxi-
mately 75% of patients with GSD I develop liver adenomas
despite apparent normoglycemia.29 In fact, liver adenomas
are the most common indication for liver transplantation
in GSD I.97 HCC is estimated to occur in 10% of patients011
with GSD I,98 most often as a result of malignant transfor-
mation of these adenomas. This clearly demonstrates HCC
risk in the absence of cirrhosis in this IEM. However,
adenomas are not a required precursor lesion because there
have been cases of GSD I with primary HCC24 and cases of
HCC in children younger than 1 year of age.95
In addition to hypoglycemia, there are additional
unique biochemical characteristics seen in GSD I patients:
lactic acidosis, hyperlipidemia, and hyperuricemia.95 The
deficiency in G6Pase complex increases glycolysis and as
result there is an increase in lipolysis leading to enhanced
production of acetyl-CoA that leads to stimulation of lipid
synthesis and inhibition of fatty acid oxidation. Liver stea-
tosis occurs because of these imbalances in fatty acids
metabolism.99 The increase in the glycolytic rate also leads
to increased flux through the P5P pathway causing altered
DNA and RNA synthesis. The high glycolytic and fatty-acid
synthesis rates are among the classical changes thought to
predispose cells to malignant transformation.85,86 In addi-
tion, several other mechanisms responsible for develop-
ment of hepatic adenomas in GSD I and their potential
transformation into HCC have been proposed including
chromosomal alterations and activation of proto-onco-
genes through dysregulation of the insulin-glucagon-
growth hormone trio29,100 (Figure 2B).
Homozygous mutations in the genes encoding the
subunits of the succinate dehydrogenase enzyme (SDH),
including SDHA and FH, result in an autosomal-recessive
IEM.101 Common features of these inherited enzyme defi-
ciencies include early-onset encephalomyopathy, hypo-
tonia, epilepsy, and failure to thrive.101 These recessive
conditions are rare and patients have a shortened life
span, thus, it is not known at present whether affected
individuals are at a higher risk for cancer. On the other
hand, heterozygous mutations in FH, SDHB (MIM
185470), SDHC (MIM 602413), SDHD (MIM 602690),
and the recently described SDHA result in the cancer
phenotypes that are inherited in an autosomal-dominant
manner.13 The heterozygous nature of the mutations
results in near normal metabolic function in somatic cells
such that patients don’t demonstrate IEM classic clinical
features. Instead, somatic loss of the remaining wild-type
allele—often associated with loss of heterozygosity of
nearby polymorphic markers—will result in tissue-specific
complete loss of function of the affected enzyme and loss
of their tumor suppressor activity in somatic tissues.102,103
Inheritance of heterozygous FH mutations predisposes
to multiple cutaneous leiomyomas, uterine leiomyomas,
adrenocortical tumors, and renal cell cancer, collectively
referred to as HLRCC.104,105 Skin leiomyomas due to germ-
line FH mutations typically present between ages 20–40
years, and there is a slight predilection in female patients.
Female carriers of FH mutations can present with early-
onset uterine leiomyomas, often requiring hysterectomy.
Mutations in FH also predispose to aggressive early-onset
RCC. Other malignancies that have been associated with
mutations in FH include ovarian mucinous cystadenomas,The AmLeydig cell tumors, leiomyosarcomas, and cerebral caver-
nomas.106
SDH is a heteroligomer containing subunits A, B, C, andD.
Mutations in genes encoding all subunits have been linked
to susceptibility to paragangliomas, which could be non-
syndromic and syndromic forms. The syndromic forms
includeCarney triad (paraganglioma, gastric stromal tumors,
and pulmonary chondromas) and Carney-Stratakis syn-
drome.16,107 The difference between these two syndromes
is the inheritance mode, which is autosomal dominant in
Carney-Stratakis syndrome, whereas the Carney triad can
result fromdenovopointmutations and genomic rearrange-
ments, the most frequent being deletion of the long arm of
chromosome 1 (1q), which includes SDHC.107
The spectrum of tumors in SDH deficiency includes
hereditary paragangliomas, gastric stromal tumors, renal
tumors, and pheochromocytomas.108,109 Cancer-predis-
posing mutations in genes encoding the SDHA, SDHB,
SDHC, and SDHD subunits of mitochondrial complex II
have all been reported.110 Mutations in SDHB are more
likely to result in metastatic paragangliomas.111 In the
US, germline mutations in SDHB and SDHD account for
approximately 70% of familial cases and approximately
8% of apparently sporadic cases of head and neck paragan-
gliomas.112
Multiple studies show that severe accumulation of succi-
nate and fumarate cause a pseudohypoxia state resulting in
an inhibition of hypoxia-inducible factor (HIF) hydroxy-
lases and leading to stabilization of activated HIF-1a and
expression of HIF target proteins such as vascular endothe-
lial growth factor (VEGF).113 HIF activation enhances
glycolysis, decreases the flux through the Krebs cycle,
and promotes transformation of certain cells as clear cell
renal cells.16 The association of mutations in VHL (associ-
ated with HIF1-alpha dysregulation), FH, SDHB and
SDHD with renal cancer109 is consistent with the notion
of renal epithelial cells are particularly susceptible to HIF-
induced transformation,16 supporting themodel that renal
cancer is a disease of cell metabolism.114 Another possible
mechanism by which HIF causes renal cancer is that both
FH and SDH deficiencies result in severe disturbance in the
electron transport chain leading to higher ROS produc-
tion.112,115,116 The reason why SDH mutations are linked
especially to paragangliomas is not clear but could be
related to the embryonic origin of paragangliomas when
an excess number of neuroblasts is generated, and SDH
deficiency could prevent necessary apoptosis117 (Figures
2C and 3).
L-2-hydroxyglutaric aciduria (MIM 236792) is caused by
mutations in the gene encoding L-2-hydroxyglutarate
dehydrogenase (MIM 609584), which localizes to mito-
chondria.118 Patients with L-2-hydroxyglutaric aciduria
are characterized by progressive ataxia, mental deficiency,
encephalopathy, subcortical leukoencephalopathy, and
cerebral atrophy. The disease is inherited in an auto-
somal-recessive manner and can be diagnosed by the
presence of elevated concentrations of L-2-hydroxyglutaricerican Journal of Human Genetics 88, 402–421, April 8, 2011 409
Figure 3. The Role of Tricarboxylic Acid
Cycle Intermediates in the Regulation of
HIF Function
Deficiencies of FH and SDH in the tricar-
boxylic acid87 cycle results in the accumu-
lation of fumarate and succinate, respec-
tively. Accumulation of fumarate and
succinate results in inhibition of the
a-KG-dependent dioxygenases (a-KG DO)
responsible for hydroxylation of the HIF,
which further impairs the recruitment of
VHL protein necessary in the HIF degrada-
tion. Isocitrate dehydrogenase deficiency
results in the depletion of a-KG, thus
decreasing the activity of some a-KG DO.
Some unique mutant alleles, IDH2* and
IDH1*,which are the result ofmodification
of the arginine at position 140 or position
172 in IDH2 (NP_002159.2) or the arginine
at position 132 of IDH1 (NP_005887.2),
confer the enzymes a novel function of
converting a-KG into D-2-hydroxygluta-
rate (D-2-HGA). This conversion results in
depletion of a-KG and an increase in the
concentration of D-2-HGA, a unique onco-
metabolite and a possible competitive
inhibitor of a-KG-dependent enzymes.
Collectively, these changes result in dysre-
gulation of the HIF-induced apoptosis,
proliferation, and differentiation under-
lying cancer mechanisms.acid in plasma, urine, or cerebrospinal fluid119 or by brain
MRI findings and molecular diagnosis. The association
between L-2-hydroxyglutaric aciduria and the develop-
ment of CNS tumors has been reported by several
groups.120,121 Moreover, a child with L-2-hydroxyglutaric
aciduria and Wilms tumor has been recently reported,
potentially expanding the tumor spectrum in this meta-
bolic disorder.122 L-2-hydroxyglutaric aciduria patients
who develop brain tumors can present with sudden and
unexpected worsening of symptoms; however, close
clinical follow up and MRI evaluation are recommended
because it is difficult to identify a brain tumor in the pres-
ence of severe underlying white matter abnormalities.121
This association is an example of how difficult it can be
to characterize the underlying molecular mechanism
leading to tumorigenesis. On the one hand, as described
below, L-2- hydroxyglutaric acid by itself was determined
to be as an oncometabolite when it accumulates in high
doses. On the other hand, L-2- hydroxyglutaric acid can
reduce the availability of a Krebs cycle intermediate,
alpha-ketoglutarate (a-KG), altering the mitochondrial
function and shifting the cells to glycolysis as a preferential
pathway for energy.
Until recently, no data were available to explain why L-2-
hydroxyglutaric aciduria predisposes the brain to oncogen-
esis. In 2008, it was found that 70% of subjects with grade
II and grade III gliomas, 12% of subjects with glioblas-
tomas, and 15%–20% of adults with acute myeloid
leukemia harbor somatic mutations in the isocitrate dehy-
drogenase 1 (IDH1 [MIM 147700]) and 2 (IDH2 [MIM410 The American Journal of Human Genetics 88, 402–421, April 8, 2147650]).123 Both IDH1 and IDH2 are NADPþ-dependent
enzymes and catalyze the oxidative decarboxylation of iso-
citrate into a-KG, a oxalosuccinate is formed as an interme-
diate product.124 IDH1 localizes to the cytoplasm and
peroxisomes, whereas IDH2 is found in the mitochon-
dria.125 IDH1 and IDH2 were first thought to be tumor
suppressor genes for which loss of function result in an
increased level of HIF (Figure 2C). However, unlike most
tumor suppressor genes, which are characterized by
dispersed mutations affecting both alleles, mutations
found in IDH1 and IDH2 were monoallelic and confined
to a single residue in the enzyme’s active site.126,127 This
led to the discovery that the mutations in IDH1 and
IDH2 are specific and cause these enzymes to acquire the
ability to convert a-KG to 2-hydroxyglutarate.128 Thus,
IDH, instead of generating a-KG, acts on the available
a-KG to generate 2-hydroxyglutarate.129,130 As of yet, it is
unclear whether there is also a decrease in a-KG contrib-
uting to pathogenesis.130,131 The debate is ongoing
whether IDH1 and IDH2 possess both oncogene and tumor
suppressor activities. In the interim, 2-hydroxyglutarate
has been designated as an oncometabolite.126 It is thought
that 2-hydroxyglutarate reduces HIF levels and in addition
potentially affects mitochondrial function and gene
expression, promoting the Warburg effect and directing
cells toward aerobic glycolysis.124
These findings have important implications for manage-
ment of patients. Mutated IDH1 and IDH2 are an impor-
tant prognostic factor. The mutant proteins result in
consumption of NADPH with sensitization of tumor cells011
Figure 4. Mitochondria as the Target and Amplifier of the
Tumorigenic Biochemical Signals
Mutations in MPV17 and DGUOK result in imbalance of the
nucleotide pool thus increasing mtDNA instability. Accumulating
mtDNA damage eventually culminates in the impairment of
oxidative phosphorylation (OXPHOS). Impaired OXPHOS causes
dysregulation of the ROS biology, propagates further genomic
and mtDNA instability, decreases apoptosis, and creates the
biochemical environment reminiscent of Warburg effect. Meta-
bolic disorders resulting in accumulation of copper (Wilson
disease) and iron (hemochromatosis) increase ROS presumably
through Fenton reaction.to irradiation and chemotherapy and, hence, increases
patients’ survival.132 In addition, future cancer drug devel-
opment will focus on developing antibodies specific for the
IDH mutation, which might be given in conjunction with
supplementation of a-KG124,132 (Figure 2C).
Citrin deficiency is an autosomal-recessive condition
caused by mutations in SLC25A1.133 The protein named
Citrin is a mitochondrial aspartate glutamate transporter
(AGC2 [MIM 600637]). Depletion of cytosolic aspartate
impairs handling of citrulline by argininosuccinate
synthase (ASS), leading to accumulation of citrulline in
plasma as well as in tissues and to impaired ureagenesis.134
Clinically, citrin deficiency can manifest itself in two
forms: citrullinemia type 2 (CTLN2 [MIM 603471]) and
neonatal intrahepatic cholestasis (NICCD [MIM
605814]). CTLN2 is distinct from citrullinemia type 1
caused by ASS deficiency (IM 215700), although CTLN2
usually causes a secondary decrease in ASS activity.
Although CTLN2 was initially observed in patients whose
ancestry was East Asian (mainly Japanese), more recent
studies suggest that citrin deficiency is a panethnic condi-
tion.135 The adult-onset disease, CTLN2, is characterized
by hyperammonemia, encephalopathy, liver fibrosis, and
steatosis usually occurring between ages 20 and 50 years.
Biochemically, CTLN2 patients show moderately elevated
plasma citrulline and in some cases markedly increase
alpha-fetoprotein levels. Multiple case reports established
an epidemiological link between citrin deficiency and
HCC.18 HCC is typically diagnosed in CTLN2 patients
between 21 to 66 years of age. Typical liver findings at
the time of HCC diagnosis include fibrosis, steatosis, and
cirrhosis, which could all contribute to HCC development.
However, there have been several cases of CTLN2 and HCC
without liver cirrhosis136 in which the etiology of the HCC
was attributed to nonalcoholic fatty changes in the liver
(Figure 2D). It is thought that citrin deficiency leads to
blocking of the malate aspartate shuttle, increasing the
ratio of cytosolic nicotinamide adenine dinucleotide to
oxidized nicotinamide adenine dinucleotide (NADH/
NADþ), which causes an increased lipid synthesis. The
high level of fatty acids leads to steatohepatitis that could
in turn cause fibrosis and liver cirrhosis-promoting
HCC.137 Another hypothesis is that citrin deficiency
behaves like a mitochondrial disorder, and damage caused
by increased oxidative stress in the liver might lead to
HCC. As during the precancerous period, the levels of 8-
hydroxy-2-deoxyguanosine, a biomarker of oxidative
stress, increase in the urine.138
In addition, because one of the unique biochemical find-
ings in citrin deficiency is hypercitrullinemia; it was
suggested that excess amounts of citrulline are tumori-
genic because its accumulation leads to an increased
uptake of thymidine by the hepatocytes enhancing DNA
synthesis and promoting proliferation.136–139 However,
the lack of reports of HCC in patients with classic citrulli-
nemia (ASS deficiency) would argue against citrulline
being the primary carcinogenic agent.The AmAberrant Mitochondrial Function
Decreased mitochondrial oxidative phosphorylation is
one of the hallmarks of cancer (Figure 4).140 Here, we will
focus on IEM generating increased ROS and imbalances
in the mitochondrial deoxynucleotide (dNTP) pool as
a primary insult predisposing to cancer formation. Imbal-
ance of the dNTP pools has been shown to induce genomic
instability in multiple ways, including base substitutions
and enhanced susceptibility to breakage as well as promo-
tion of chromosomere re-arrangement, breakage, and
loss,141,142 all of which could predispose to cancer.
Increased ROS has also been linked with DNA damage
through oxidation of nucleotide bases143,144 promoting
cell growth and hence contributing to carcinogenesis.143
mtDNAdepletion syndromes (MDDSs) represent a group
of autosomal-recessive disorders resulting from mutations
in the nuclear-encoding genes participating in biogenesis
of mtDNA and homeostasis of the mitochondrial nucleo-
tide pool140. Although data are limited, a review of 76
patients with deoxyguanosine kinase (dGK) deficiency
caused by mutations in DGUOK (MIM 601465) demon-
strated that two subjects developed HCC.145 In addition,
mutations in MPV17 (MIM 137960), which encodes the
mitochondrial inner membrane protein MPV17 and has
been found to cause hepatocerebellar mtDNA depletion,
were also found to be associated with HCC.146,147 Unlike
dGK, the exact function of MPV17 is unknown.148
The mechanism of HCC tumor development in dGK
deficiency could be related to neonatal hepatitis orerican Journal of Human Genetics 88, 402–421, April 8, 2011 411
cirrhosis. 149 In addition, it is interesting to note that
analysis of sporadic HCC samples demonstrates somatic
mtDNA depletion.25, 27,150 Depletion of mtDNA from
cancerous cells enhances the tumorigenic phenotype
in vitro and in xenograft models of human breast
cancer.151 Both human breast cancer and prostate cancer
cells depleted of mtDNA were found to exhibit a more
aggressive cancer phenotype.152 In addition, it has been
demonstrated in animal models that unbalanced mito-
chondrial dNTP pools are mutagenic,153,154 and it can be
hypothesized that this could be the mechanism respon-
sible for the development of HCC in dGK disease. It has
been suggested that MPV17 plays a role in controlling
mtDNA maintenance and oxidative phosphorylation
activity in mammals and yeast. The SYM1, the ortholog
of MPV17 in Saccharomyces cerevisiae, functions in the
cellular response to metabolic stress and in maintaining
mtDNA integrity and stability.155 Thus, in the absence of
functional MPV17, there is a risk for increased generation
of ROS that could stimulate the development of HCC by
itself or lead to increased mutation rate.
Another example of mitochondrial disorder associated
with tumor growth is myoclonus epilepsy and ragged-red
fibers (MERRF [MIM 545000]) syndrome, a progressive
mitochondrial encephalopathy characterized by
myoclonic seizures, ataxia, dementia, and hypotonia.156
It results from the mtDNA point mutation that changes
a highly conserved adenine to guanine at nucleotide
8344 in the mitochondrial tRNA for lysine, (tRNA-Lys
[MIM 590060], m.8344A>G).157,158 Familial multiple
lipomas symmetrically located around the neck have
been described in several patients with MERRF159,160 and
in carriers of the m.8344A>G mutation. The finding of
a high proportion of mutated mtDNA, together with
abnormal mitochondria in lipomas from carriers, suggest
that the appearance of the lipoma is a primary manifesta-
tion in adipose tissue.157 It could be that the defect in
oxidative phosphorylation might interfere with normal
adipocyte maturation.157
Therapy Targeting Metabolic Pathways Dysregulated
in Cancer Cells
In this section, we describe how the recognition of meta-
bolic abnormalities in cancer cells deepened our under-
standing of tumorigenesis, allowing the development of
new cancer treatments. We will discuss two examples: (1)
ASS deficiency in tumors as a concept of nutrient-metabo-
lite deprivation and (2) targeting drugs for mitochondrial
dysfunction in tumor cells putting them at survival disad-
vantage through mechanisms mediated by ROS.
A noncancerous eukaryotic cell is able to adapt to nutri-
tional deprivation by breaking down its reserves and
synthesizing essential components to survive until nutri-
tional status improves. In contrast, cancer cells are unable
to synthesize certain amino acids161 and are thus depen-
dent on the supply of these amino acids from external sour-
ces. One can exploit this nutritional difference to explore412 The American Journal of Human Genetics 88, 402–421, April 8, 2new therapeutic approaches. This strategy was applied to
slow the growth of tumor cells through depletion of
arginine. In humans, arginine is a nonessential amino
acid because it can be synthesized from citrulline in two
steps by using ASS and argininosuccinate lyase (MIM
608310) enzymes. However, in vitro experiments demon-
strated that of 80% of primary and established cancer cell
lines tested, the cellswere unable to grow inmedia deprived
of arginine because of their inability to convert citrulline to
arginine, making arginine an essential amino acid.162 In
parallel, ASS deficiencywas demonstrated in several human
cancers including melanoma, HCC and prostate carci-
noma.163 In addition it was found that ASS deficiency is
significantly associated with increased lymphatic dissemi-
nation of esophageal carcinoma164and with osteosarcoma
lung metastasis.165 Hence, arginine depletion could have
beneficial effect specifically in those tumors with low ASS
expression and poor prognosis. Much older studies demon-
strated thatMycoplasma hominis can deplete arginine from
tumor cells by using an enzymatic pathway not present in
the mammalian cell host, i.e., arginine deiminase (ADI),
which converts arginine to citrulline allowing M. hominis
to target and kill specifically human tumor cell lines.166–168
Of interest, this pathway is also involved in the generation
of ATPwhen two other enzymes, ornithine transcarbamoy-
lase and carbamate kinase, act in concert with ADI in
M. hominis.169 Recently, these observations made half
a century ago, led to the development of a new treatment
approach.170 Pegylated ADI depletes intracellular arginine
in cancer cells, which have an acquired ASS deficiency
and thus are unable to resynthesize arginine from citrul-
line.171 Phase I and II clinical trials with pegylated ADI led
to a 47% response rate in patients with unresectable HCC,
and a 25% response rate in patients with metastatic mela-
noma.172,173 Additional cancer types are in the pipeline
for clinical treatment trials. Hence, understanding of meta-
bolic pathways differentiating the survival mechanism of
normal cells fromcancer cells has enabled the development
of a specific therapy with beneficial clinical outcomes.
The mitochondria are key participants in ATP produc-
tion, cell death, and ROS homeostasis. Multiple studies
suggest that cancer cells’ ability to grow and proliferate
under increased ROS stress might be because of mitochon-
drial dysfunction leading to decreased apoptosis143,174
Hence, therapeutic strategies could rely on three main
differences between the mitochondria function in cancer
versus normal cells: the higher glycolytic activity, the
increase in ROS, and the differential regulation of
apoptosis observed in cancer cells.175,176 Indeed, defects
in mitochondrial function have long been suspected to
contribute to the development and possibly progression
of cancer. As described in the introduction, Warburg
described in 1956 the unique tumor phenotype where
even in the presence of oxygen, tumor cells preferentially
metabolize glucose to lactic acid and not to ATP as occurs
in normal cells.2 This phenomenon commonly referred
to as the Warburg effect suggests that mitochondrial011
alterations could provide unique therapeutic targets in
various cancer types. In the late 1970s, the role of mito-
chondria in cancer was bolstered by the discovery that
hepatic tumors (hepatomas) express hexokinase (EC
2.7.1.1) type II, (HK-2 [MIM 601125]), whereas normal
hepatic cells express hexokinase IV, HK-4, also known as
glucokinase (GCK [MIM 138079]). These two hexokinases
differ in their cellular localization and in their enzyme
kinetics, i.e., HK-2 interacts with the outer mitochondrial
membrane protein voltage-dependent anion channel
(VDAC) also known as mitochondrial porin,177 and has
a 250-fold lower KM for glucose meaning, much higher
glucose affinity relative to the cytosolic HK-4. HK-2 locali-
zation gives it preferential access to mitochondrial
generated ATP enhancing the rate of glycolysis as well as
protection from feedback inhibition by its product
glucose-6-phosphate (G6P). Hence, tumors overproducing
HK-2 can produce G6P at high rate providing support for
uncontrolled tumor proliferation.178–180 This scientific
discovery led quickly to clinical applications. By using
a deoxy analog of glucose (2-deoxy-D-glucose)that can be
phosphorylated by HK-2 but not metabolized further,
and that had been labeled with the positron emitter 18F,
it became possible to image cancers for the first time in
human patients.181 This imaging technology now widely
known as positron emission tomography (PET scan) is
utilized worldwide in humans for detecting all types of
malignant tumors and monitoring their treatment.181
When it was later shown that the complex HK-2-VDAC
also has anti-apoptotic effects,182 it was logically hypothe-
sized that targeting tumor glycolysis by silencing HK-2 or
disruption of its interaction with VDAC, would halt tumor
proliferation and induce apoptosis.183 Indeed, small mole-
cules analogs of pyruvate targeting HK-2 have been shown
to be highly effective in animal cancer models and are now
in preclinical trials.184
Changes in mtDNA content and mtDNA mutations
leading to altered expression and activity of respiratory
chain subunits, have also been shown to increase tumori-
genesis in part because of an increased ROS production.116
A clear demonstration that a mtDNA mutation in cancer
cells could be functionally significant came from a study
that introduced a known pathogenic mtDNA mutation
into a prostate cancer cell line, resulting in increased
tumorigenicity in nude mouse transplantation
studies.185,186 There are several differences between the
nuclear and mtDNA that might be responsible for
increased instability in tumors including: the close prox-
imity between the mtDNA and the site of ROS production,
mtDNA doesn’t have introns or histones, and mtDNA has
limited DNA repair machinery. Undoubtedly, increased
ROS production that occurs with mitochondrial dysfunc-
tion is an important contributor to tumorigenesis,187
resulting in a vicious cycle in which mtDNA mutations
lead to more ROS production, which in turn generates
more mtDNA alterations that lead to increased genomic
instability and often to cancer.143There are multiple otherThe Amways by which increased ROS contributes to tumorigenesis
including: causing changes in nuclear gene expression,188
acting as a stimulant in the proliferative response189,190 by
affecting the conformation and phosphorylation status of
key proteins in signaling pathways as MAPK191 Akt192,187
and by influencing DNA- binding ability of various tran-
scription factors as Ets-1193and p53.194 With the increased
ROS, cancer cells are more dependent on antioxidant
defense and it was indeed demonstrated that human
leukemia and ovarian cancer cells are more sensitive to
superoxide dismutase inhibition than normal cells.175
Finally, the apoptotic regulator Bcl-2 localizes to the mito-
chondrial outer membrane where it prevents the release of
cytochrome c and other proapoptotic proteins.176 Bcl-2
proteins are overexpressed in many cancers as the result
of either translocations or dysregulation contributing to
tumorigenesis. Indeed, Bcl-2 inhibitors have shown to
induce cancer cell apoptosis by promoting cytochrome c
release and initiating tumor regression in mice.195,196
In summary, somatic mutations of either nuclear en-
coded mitochondrial genes or mtDNA mutations and
mtDNA depletion are frequent in solid and hematological
malignancies.197 Thus, as suggested by Warburg, mito-
chondrial alterations provide unique therapeutic targets
in various cancers.
Interaction of IEM and Cancer Therapy
IEM complicated by cancer present a unique clinical chal-
lenge because there is an increased risk for toxicity result-
ing from the additional interaction between chemo-
therapy and the IEM. This gene X environment
interaction is characterized at the simplest level by the
catabolic state associated with chemotherapy that would
worsen or potentially destabilize any patient with an
IEM. Alternatively, it might be specific for the underlying
enzyme derangement and the therapy employed. Few
cases have been described to date but undoubtedly more
will emerge with the increased survival of patients with
IEM. Understanding the metabolic abnormality could
prevent drug toxicity and increase treatment benefits.
As most chemotherapy drugs are metabolized in the
liver, treating patients with liver-related IEM require
specific attention to treatment dosage. A recent case
describes a patient with Rotor syndrome (MIM 237450)
who developed ovarian cancer.198 Rotor syndrome is
a rare congenital disorder characterized by functional
hyperbilirubinemia. The ovarian cancer was treated with
Paclitaxel, a drug metabolized in the liver and excreted
into the bile. The treating physicians reduced Paclitaxel
dosage by 50% based on the diagnosis of Rotor syndrome
and the patient experienced neither clinical nor biochem-
ical derangement, and treatment was well tolerated.198
In contrast, another paper describes two patients with
metastatic colon cancer and Gilbert syndrome (MIM
143500) treated with CPT-11-based chemotherapy who
experienced severe toxicity.199 Patients with Gilbert syn-
drome have deficient uridine diphosphate glucuronosylerican Journal of Human Genetics 88, 402–421, April 8, 2011 413
Figure 5. The Summary of Converging Mechanisms in IEM
Underlying Tumorigenesis
Abnormal cell energy metabolism encompasses Warburg effect,
increased flux through P5P shunt, increased synthesis of fatty
acids and triglycerides, and glutamine dependence, which can
be seen patients with IEMs. Alterations in the nucleotide pools,
mtDNA mutations, and direct mutagenesis by abnormal interme-
diate metabolites come under the general mechanism of genomic
instability. Finally, alterations in the ROS biology can either
promote or inhibit cellular growth depending on the intracellular
context. Abnormalities in the energy metabolism, genomic insta-
bility, and altered ROS biology interact and might amplify each
other. Each disorder might have one or more mechanisms
involved in tumorigenesis. The net effect of these changes is not
necessarily direct tumorigenesis, but rather decreased threshold
for tumor transformation.transferases (UGTs [MIM 191740]), and the drug CPT-11 is
hydrolyzed to its active metabolite through conjugation by
UGT.Hence, in all cycles, patients showed evidence of severe
neutropenia and diarrhea, and treatment of patients with
Gilbert syndrome should anticipate this increase in toxicity.
A different example of chemotherapy and toxicity in
IEM involves hematological abnormalities such as those
seen in GD. Thrombocytopenia is a common finding in
patients with GD, resulting from two related mechanisms,
decreased platelet production in the bone marrow and
splenic sequestration. Other clinical manifestations reflect-
ing the hematological involvement of this disease include
anemia, bleeding, and pancytopenia. Cancer treatment of
GD patients with chemotherapy has often been discontin-
ued because hematological toxicity due to chemotherapy
exacerbated the pancytopenia already present in GD,
emphasizing the need for the right regimen.200
Together, these cases demonstrate that better under-
standing of the pathophysiology of the IEM leads to
a better choice of anticancer therapy and thus improves
the treatment of cancer in these patients.
Summary
Multiple evidences suggest an intimate link between tumor-
igenesis and disrupted metabolic regulation (Figure 5). By
following the Vogelstein model for multistep accumulation
of mutation for carcinogenesis,201 one can understand how
an IEM can lead to increased mutagenesis by causing
increasing DNA damage (Figure 1). Thus, not surprisingly,
long-term follow up of patients with IEM is starting to reveal
specific patterns of cancer susceptibility (Table 1).
In IEM, the initiation of carcinogenesis starts from germ
line mutations in either the mtDNA or nuclear DNA. This
core disruptive event in metabolism predisposes cells to
malignant transformation by a variety of putative mecha-
nisms including increased ROS and depletion of the mito-
chondrial dNTP pools, as well as accumulation of toxic
metabolites or a compensatory channeling of metabolites
to an alternative pathway. The rarity of IEM disorders
and the frequency of cancer development make a cause
and effect argument clear. Similarly, the observation that
specific IEM tend to develop unique types of cancer further
argues against coincidental findings and suggests that the
specific metabolic change is involved in the development
of the specific cancer. However, as described here, the prev-
alence of HCC in a variety of IEM also argue that premature
cirrhosis and other events might constitute a shared path-
ophysiologic pathway.
Hence, IEM patients offer an opportunity to understand
specific cancer pathogenesis that could aid in developing
rationale treatments relevant for these types of cancers
when they occur sporadically. Because IEM in general are
rare disorders, the quantification of cancer risk in each
disorder is difficult. We hope this review will bring
increased awareness to the cancer susceptibility in the
described IEM and lead to larger collaborative studies to
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